Clinical Trials Logo

Meropenem clinical trials

View clinical trials related to Meropenem.

Filter by:
  • None
  • Page 1

NCT ID: NCT06426836 Recruiting - Pharmacokinetics Clinical Trials

Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)

PADECMO
Start date: August 19, 2016
Phase: N/A
Study type: Interventional

Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).

NCT ID: NCT03790631 Recruiting - Efficacy Clinical Trials

The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring

OPTIMAL TDM
Start date: January 14, 2019
Phase:
Study type: Observational

Little is known of beta-lactam antibiotics' true therapeutic plasma concentration range. The aims of this study are to define evidence-based, safe and effective upper and lower limits of the plasma concentrations of imipenem, meropenem, amoxicillin, flucloxacillin, piperacillin, ceftazidime and cefepime in patients at increased risk of serious bacterial infections and currently understudied pharmacokinetics (the critically ill, the elderly, and the immunosuppressed). This prospective observational study will include adult patients with suspected or confirmed systemic bacterial infection receiving one of the above-named antibiotics and hospitalized in intensive-care, step-down, or hematology-oncology units of the Geneva University Hospitals (HUG). Eligible patients will be identified via the electronic health record (EHR). Patients receiving traditional intermittent dosing or prolonged infusions will undergo TDM for at least one intermediate (mid-interval) and one trough level at 24 hours (-12 or +48 hours) after the therapy's start. Patients receiving continuous infusions will undergo TDM for at least one steady-state level. Clinical course will be observed for 30 days from the start of the study antibiotic (1st day of study antibiotic =day 1). The primary outcome is incidence of clinical toxicity through day 30 after start of study antibiotic (as stratified by BL trough concentration). Secondary outcomes are listed below.

NCT ID: NCT02456974 Recruiting - Pharmacokinetics Clinical Trials

Antibiotic Dosing in Pediatric Intensive Care

ADIC
Start date: May 2012
Phase:
Study type: Observational [Patient Registry]

Pharmacokinetics of antibiotics in critically ill neonates, infants and children